Denali Therapeutics (DNLI) Treasury Shares (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Treasury Shares data on file, last reported at $6.9 million in Q1 2026.

• Quarterly Treasury Shares rose 41.8% year-over-year to $6.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.9 million (up 41.8% YoY) and the FY2025 annual result came in at $5.1 million, up 24.13% from the prior year.
• Treasury Shares grew to $6.9 million in Q1 2026 per DNLI's latest filing, from $5.1 million in the prior quarter.
• Across five years, Treasury Shares topped out at $6.9 million in Q1 2026 and bottomed at $2.9 million in Q2 2022.
• The 5-year median for Treasury Shares is $4.0 million (2024), against an average of $4.2 million.
• The widest annual swing landed in 2024, when Treasury Shares rose 7.43%; it then jumped 41.8% in 2026.
• Tracing DNLI's Treasury Shares over 5 years: stood at $3.3 million in 2022, then advanced by 9.14% to $3.6 million in 2023, then rose by 13.57% to $4.1 million in 2024, then rose by 24.13% to $5.1 million in 2025, then soared by 34.18% to $6.9 million in 2026.
• Per Business Quant, the three latest DNLI Treasury Shares figures stand at $6.9 million (Q1 2026), $5.1 million (Q4 2025), and $5.2 million (Q3 2025).

Peer Comparison